#India #healthcare #Mumbai #pharmaceuticals #Piramal Pharma

Piramal Pharma Limited Reports Impressive Q1 FY27 Results

Piramal Pharma Limited, recognized as one of the leading pharmaceutical and healthcare companies globally, has recently announced its financial outcomes for the first quarter of the fiscal year 2027, which concluded on June 30, 2026. The report highlights an impressive trajectory of growth and operational excellence across its diverse business segments including Contract Development and Manufacturing (CDMO), Complex Hospital Generics (CHG), and Consumer Healthcare (PCH).

Key Financial Highlights

The financial results for Q1 FY27 reflect a robust increase in revenue and profitability:

• - Revenue from Operations reached ₹2,270 crore, an increase of 17% compared to ₹1,934 crore in Q1 FY26.
• - The CDMO segment generated ₹1,187 crore, up 19% year-over-year, indicating strong performance in contract manufacturing.
• - CHG revenue increased by 17%, reaching ₹743 crore, while the Consumer Healthcare division saw growth of 15%, contributing ₹347 crore.
• - EBITDA posted a remarkable growth of 72%, amounting to ₹285 crore, enhancing the EBITDA margin to 12.5% from 8.5% in the previous year.
• - Publicly, the Profit After Tax (PAT) for the quarter registered a loss of ₹69 crore versus a loss of ₹102 crore in the prior year, showcasing a 32% improvement.

Nandini Piramal, the Chairperson of Piramal Pharma Limited, emphasized the strong start to FY27, noting that all business segments observed solid growth, aided by strategic initiatives, operational improvements, and market expansions. The company's proactive approach in enhancing its distribution and sales capabilities has effectively driven this momentum, alongside maintaining its leadership in key therapeutic areas.

Business Operations Outlook

Piramal Pharma's commitment to quality and operational excellence has yielded significant operational metrics:

• - The CDMO unit demonstrated extensive growth through improved capacity utilization and rigorous operational discipline, which has been pivotal in expanding the EBITDA margins despite inflationary pressures.
• - The company is also expanding its ADC (Antibody-Drug Conjugate) capabilities, enhancing its production capacity for sterile injectable formulations, which is expected to boost growth in the coming quarters.
• - Within the Complex Hospital Generics sector, Piramal has retained its leadership in the US market for Sevoflurane, and is achieving notable progress with inhalational anesthetics outside the US.
• - The Consumer Healthcare segment notably saw a 23% growth in power brands, which significantly contributes to revenue through strong e-commerce channels.

Strategic Initiatives

Piramal’s diversified product portfolio continues to strengthen its market position through:

• - Increased investments in high-quality manufacturing processes and the establishment of strategic partnerships, such as with Ajinomoto Bio-Pharma Services, to advance next-generation conjugation technologies.
• - Launching the new brand identity, i-choose, that consolidates its women’s intimate care products, further enhancing brand visibility and consumer engagement.
• - Commitment to maintaining premium brand visibility through strategic media and trade advertising investments, accounting for approximately 12% of sales.

Overall, Piramal Pharma Limited's Q1 FY27 results depict a company poised for continued growth and sustainability in a dynamic marketplace. The focus on operational excellence, quality compliance, and strategic partnerships reflects the company’s dedication to maintaining a competitive edge in the global pharmaceutical and healthcare landscape. With a strong pipeline and an agile approach to market demands, Piramal Pharma is set to navigate the complexities of the industry successfully, emphasizing health, wellness, and innovation in every endeavor.